Latest Addrenex Pharmaceuticals Stories
Addrenex Pharmaceuticals has announced that the FDA has approved its investigational new drug application for ADX415, a novel hypertension drug. With the approval, Addrenex has launched a Phase II clinical trial to study ADX415 as a targeted therapy for hypertension.
Sciele Pharma and Addrenex Pharmaceuticals have announced that the preliminary analysis of the Phase III clinical study investigating the use of Clonicel for the treatment of attention deficit hyperactivity disorder has shown statistically significant improvement over placebo.
DURHAM, N.C., Sept. 10 /PRNewswire/ -- A drug that diminishes the body's hyper-reactivity to stress has been shown to significantly reduce symptoms of attention-deficit hyperactivity disorder (ADHD) in children, according to a phase 3 clinical trial conducted by Addrenex Pharmaceuticals.
Sciele Pharma, Inc.
DURHAM, N.C., Aug. 19 /PRNewswire/ -- Addrenex Pharmaceuticals ( http://www.addrenex.com/ ) has made three strategic hires this month to further its goal of identifying and developing as many new drug candidates as possible over the next 18 months.
DURHAM, N.C., July 1 /PRNewswire/ -- Two years after Addrenex Pharmaceuticals set it sights on building a new class of drugs to regulate "adrenergic excess," the small Durham company has signed its second major deal with Sciele Pharma, this time to co-develop a new compound for hypertension and other potential indications.
- A mania for the use of printing-types; a strong propensity to write for publication.